This Article Full Text Full Text (PDF) Supplementary Data Correction (v68,p6030) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Garlich, J. R. Articles by Durden, D. L. Search for Related Content PubMed PubMed Citation Articles by Garlich, J. R. Articles by Durden, D. L.

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

¹ Section of Hematology/Oncology, Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta and ² Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia; ³ Semafore Pharmaceuticals, Indianapolis, Indiana; and ⁴ Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Donald L. Durden, Aflac Cancer Center and Blood Disorders Service, Emory University School of Medicine, Atlanta, GA. Phone: 404-778-5118; E-mail: dldurde{at}emory.edu.

PTEN and the pan phosphoinositide 3-kinase (PI3K) inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1benzopyran-4-one (LY294002) exert significant control over tumor-induced angiogenesis and tumor growth in vivo. The LY294002 compound is not a viable drug candidate due to poor pharmacologic variables of insolubility and short half-life. Herein, we describe the development and antitumor activity of a novel RGDS-conjugated LY294002 prodrug, termed SF1126, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment, resulting in enhanced delivery of the active compound to the tumor vasculature and tumor. SF1126 is water soluble, has favorable pharmacokinetics, and is well tolerated in murine systems. The capacity of SF1126 to inhibit U87MG and PC3 tumor growth was enhanced by the RGDS integrin (vβ3/5β1) binding component, exhibiting increased activity compared with a false RADS-targeted prodrug, SF1326. Antitumor activity of SF1126 was associated with the pharmacokinetic accumulation of SF1126 in tumor tissue and the pharmacodynamic knockdown of phosphorylated AKT in vivo. Furthermore, SF1126 seems to exhibit both antitumor and antiangiogenic activity. The results support SF1126 as a viable pan PI3K inhibitor for phase I clinical trials in cancer and provide support for a new paradigm, the application of pan PI3K inhibitory prodrugs for the treatment of cancer. [Cancer Res 2008;68(1):206–15]

This article has been cited by other articles:

				Correction: Pan PI3K Inhibitor Prodrug for Cancer Therapy Cancer Res., July 15, 2008; 68(14): 6030 - 6030. [Full Text] [PDF]

				N. Dey, H. E. Crosswell, P. De, R. Parsons, Q. Peng, J. D. Su, and D. L. Durden The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration Cancer Res., March 15, 2008; 68(6): 1862 - 1871. [Abstract] [Full Text] [PDF]